Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on ...

High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA’s Fast Track designation for ateganosine ...

This meeting will serve as a kick-off for the National Academies consensus study Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary Biotechnology. This me ...

SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech (ONCY) ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, ...

A New Orleans-based biotech company has developed a breakthrough non-opioid pain medication, which is backed by funding from Ochsner Ventures, the investment arm of Ochsner Health, and from Gulf South ...

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best US stocks to buy under $50. On January 15, analysts at Deutsche Bank reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and ...

Potential breakthrough therapeutic for estimated $50+ billion global immunotherapy market; first and only telomere-targeting anticancer agent in clinical development anywhere CHICAGO, Jan. 20, 2026 ...

The National Academies of Sciences, Engineering, and Medicine will convene an ad hoc study Committee on Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary ...

By Oncolytics Biotech® Inc. Feb 19, 2025 Feb 19, 2025Updated Feb 19, 2025 Oncolytics Biotech Inc Logo By Oncolytics Biotech® Inc. Regulatory progress in pancreatic cancer and recent clinical data ...